Prostate Cancer Deaths Halved with Early Detection, new Data Shows
London, UK – October 14, 2025 – Routine prostate-specific antigen (PSA) testing can reduce the risk of death from prostate cancer by up too 50%, according to compelling new research presented today at the European Urology Association Congress. The findings underscore the critical importance of proactive screening for all men, especially as prostate cancer often presents with no noticeable symptoms in its early, most treatable stages.
Prostate cancer is the most common cancer in men worldwide, with an estimated 1.4 million new cases diagnosed globally in 2023. While treatment is highly effective when the disease is detected early, delayed diagnosis frequently leads to more aggressive interventions and considerably diminished survival rates. This research reinforces the argument for widespread PSA testing as a vital tool in combating the disease and saving lives.
The study, analyzing data from over 200,000 men over a 20-year period, demonstrated a clear correlation between regular PSA screening and a considerable decrease in prostate cancer mortality. Men who underwent consistent PSA testing were found to have a 40-50% lower risk of dying from the disease compared to those who did not.
PSA is a protein produced by cells in the prostate gland. Elevated levels in the blood can indicate the presence of prostate cancer, even though other factors, such as age and prostate size, can also influence PSA levels. Experts emphasize that PSA testing is not foolproof and can sometimes lead to false positives, prompting unneeded biopsies. However, they maintain that the benefits of early detection far outweigh the risks.
“This data provides further evidence that PSA testing,when combined with informed decision-making and appropriate follow-up,is a powerful weapon in the fight against prostate cancer,” stated Dr. James Eastham,a leading urologist involved in the research. “We urge all men, particularly those over 50, or those with a family history of the disease, to discuss PSA testing with their doctor.”
Current guidelines regarding PSA screening vary internationally. The U.S. Preventive Services Task Force recommends a shared decision-making approach, where men are informed of the potential benefits and risks of testing and can decide whether or not to proceed. However, many European countries have more proactive screening programs in place. The new research is expected to fuel further debate and potentially lead to revised screening recommendations globally.
